ReviewLung Cancer (Auckland, N.Z.)2016
Modern management of malignant pleural mesothelioma.
Review in Lung Cancer (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma.Cell death & disease · 2026Article
- Metastatic spread of pleural mesothelioma to the peritoneum and gallbladder presenting as recurrent acute cholecystitis.Oxford medical case reports · 2025Article
- Hyperthermic Intrathoracic Chemoperfusion and the Role of Adjunct Immunotherapy for the Treatment of Pleural Mesothelioma.Biomolecules · 2025Review
- Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.Current treatment options in oncology · 2025Review
- A study of somaticPleura and peritoneum · 2023Article
- Living beyond expectations: a qualitative study into the experience of long-term survivors with pleural mesothelioma and their carers.BMJ open respiratory research · 2022Article
- Tongue: the unusual site in malignant pleural mesothelioma.BMJ case reports · 2021Article
- Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma.Cell death discovery · 2020Article
- Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.International journal of molecular sciences · 2020Article
- Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review.International journal of molecular sciences · 2020Review
- Establishment and characterization of CRISPR/Cas9-mediated NF2Cancer science · 2019Article
- Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy.Clinical case reports · 2018Article
- Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study.Journal of thoracic disease · 2018Article
- Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.Journal of thoracic disease · 2018Review
- Article
- Malignant mesothelioma presenting as recurrent hydro-pneumothorax: An atypical case presentation and literature review.Respiratory medicine case reports · 2018Article
- Novel systemic therapy against malignant pleural mesothelioma.Translational lung cancer research · 2017Review
- Predicting Mesothelioma Using Artificial Intelligence: A Scoping Review of Common Models and Applications.Technology in cancer research & treatmentArticle
- Trimodality treatment in malignant pleural mesothelioma - Ordeal or real deal?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) is a deadly disease that produces a significant worldwide health care burden. The majority of cases are associated with prior asbestos exposure, but recent studies have identified a possible genetic predisposition in a minority of patients. Historically, obtaining a pathologic diagnosis of MPM was challenging, but with current pathological techniques, a secure diagnosis is possible in the majority of patients. Curative therapy for MPM remains elusive, and the primary treatment option for fit patients is platinum-based chemotherapy. Encouraging recent reports suggest that there may be a benefit to the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in MPM. Selected patients may be considered for aggressive surgical approaches, but there is considerable controversy regarding the true benefit of surgery and multimodality therapy in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.